PL3768265T3 - Nowy, aktywny na poziomie ośrodkowego układu nerwowego agonista greliny i jego zastosowania w medycynie - Google Patents
Nowy, aktywny na poziomie ośrodkowego układu nerwowego agonista greliny i jego zastosowania w medycynieInfo
- Publication number
- PL3768265T3 PL3768265T3 PL19715003.0T PL19715003T PL3768265T3 PL 3768265 T3 PL3768265 T3 PL 3768265T3 PL 19715003 T PL19715003 T PL 19715003T PL 3768265 T3 PL3768265 T3 PL 3768265T3
- Authority
- PL
- Poland
- Prior art keywords
- medical uses
- ghrelin agonist
- active ghrelin
- new centrally
- centrally
- Prior art date
Links
- 102000012004 Ghrelin Human genes 0.000 title 1
- 101800001586 Ghrelin Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18163425.4A EP3542799A1 (en) | 2018-03-22 | 2018-03-22 | New centrally-active ghrelin agonist and medical uses thereof |
| PCT/EP2019/056438 WO2019179878A1 (en) | 2018-03-22 | 2019-03-14 | New centrally-active ghrelin agonist and medical uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3768265T3 true PL3768265T3 (pl) | 2022-08-29 |
Family
ID=61763810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19715003.0T PL3768265T3 (pl) | 2018-03-22 | 2019-03-14 | Nowy, aktywny na poziomie ośrodkowego układu nerwowego agonista greliny i jego zastosowania w medycynie |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US12005056B2 (pl) |
| EP (2) | EP3542799A1 (pl) |
| JP (1) | JP7182638B2 (pl) |
| KR (1) | KR102676216B1 (pl) |
| CN (3) | CN111902142B (pl) |
| CA (1) | CA3089440A1 (pl) |
| DK (1) | DK3768265T3 (pl) |
| ES (1) | ES2918329T3 (pl) |
| HR (1) | HRP20220905T8 (pl) |
| HU (1) | HUE059248T2 (pl) |
| LT (1) | LT3768265T (pl) |
| MA (1) | MA52080A (pl) |
| MD (1) | MD3768265T2 (pl) |
| PL (1) | PL3768265T3 (pl) |
| PT (1) | PT3768265T (pl) |
| RS (1) | RS63409B1 (pl) |
| SI (1) | SI3768265T1 (pl) |
| WO (1) | WO2019179878A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL308971A (en) | 2021-06-02 | 2024-01-01 | Helsinn Healthcare Sa | UREA DERIVATIVES OF PIPERIDINE FOR USE AS ENTROPIC AGENTS |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012113103A1 (en) | 2011-02-25 | 2012-08-30 | Helsinn Healthcare S.A. | Asymmetric ureas and medical uses thereof |
| TWI690512B (zh) | 2014-03-07 | 2020-04-11 | 瑞士商赫爾辛保健股份有限公司 | 對位取代的不對稱脲及其醫療用途 |
-
2018
- 2018-03-22 EP EP18163425.4A patent/EP3542799A1/en not_active Withdrawn
-
2019
- 2019-03-14 WO PCT/EP2019/056438 patent/WO2019179878A1/en active Application Filing
- 2019-03-14 EP EP19715003.0A patent/EP3768265B1/en active Active
- 2019-03-14 JP JP2020544890A patent/JP7182638B2/ja active Active
- 2019-03-14 PT PT197150030T patent/PT3768265T/pt unknown
- 2019-03-14 ES ES19715003T patent/ES2918329T3/es active Active
- 2019-03-14 CN CN201980021301.3A patent/CN111902142B/zh active Active
- 2019-03-14 PL PL19715003.0T patent/PL3768265T3/pl unknown
- 2019-03-14 SI SI201930261T patent/SI3768265T1/sl unknown
- 2019-03-14 DK DK19715003.0T patent/DK3768265T3/da active
- 2019-03-14 US US16/982,107 patent/US12005056B2/en active Active
- 2019-03-14 HR HRP20220905TT patent/HRP20220905T8/hr unknown
- 2019-03-14 CN CN202310931935.0A patent/CN116983307A/zh active Pending
- 2019-03-14 MA MA052080A patent/MA52080A/fr unknown
- 2019-03-14 MD MDE20210098T patent/MD3768265T2/ro unknown
- 2019-03-14 RS RS20220692A patent/RS63409B1/sr unknown
- 2019-03-14 CA CA3089440A patent/CA3089440A1/en active Pending
- 2019-03-14 CN CN202310931999.0A patent/CN116983308A/zh active Pending
- 2019-03-14 KR KR1020207029769A patent/KR102676216B1/ko active IP Right Grant
- 2019-03-14 HU HUE19715003A patent/HUE059248T2/hu unknown
- 2019-03-14 LT LTEPPCT/EP2019/056438T patent/LT3768265T/lt unknown
-
2024
- 2024-05-02 US US18/653,685 patent/US20240293388A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019179878A1 (en) | 2019-09-26 |
| ES2918329T3 (es) | 2022-07-15 |
| JP7182638B2 (ja) | 2022-12-02 |
| CN111902142A (zh) | 2020-11-06 |
| JP2021516675A (ja) | 2021-07-08 |
| CN111902142B (zh) | 2023-10-20 |
| PT3768265T (pt) | 2022-05-19 |
| EP3542799A1 (en) | 2019-09-25 |
| EP3768265B1 (en) | 2022-05-04 |
| CN116983307A (zh) | 2023-11-03 |
| HRP20220905T8 (hr) | 2022-12-23 |
| HUE059248T2 (hu) | 2022-11-28 |
| CA3089440A1 (en) | 2019-09-26 |
| RS63409B1 (sr) | 2022-08-31 |
| MD3768265T2 (ro) | 2022-09-30 |
| US12005056B2 (en) | 2024-06-11 |
| CN116983308A (zh) | 2023-11-03 |
| DK3768265T3 (da) | 2022-07-25 |
| MA52080A (fr) | 2021-06-02 |
| HRP20220905T1 (hr) | 2022-10-14 |
| EP3768265A1 (en) | 2021-01-27 |
| KR20200135814A (ko) | 2020-12-03 |
| LT3768265T (lt) | 2022-06-27 |
| SI3768265T1 (sl) | 2022-08-31 |
| KR102676216B1 (ko) | 2024-06-17 |
| US20240293388A1 (en) | 2024-09-05 |
| US20230158007A1 (en) | 2023-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201808566D0 (en) | Improved device and components thereof | |
| HUE063120T2 (hu) | LRRC33-inhibitorok és alkalmazásuk | |
| IL282350A (en) | Bernani-RGMC inhibitors and their use | |
| IL276814A (en) | Indazole-3-carboxamides converted in 5-heteroaryl and their preparation and use | |
| IL269836B (en) | Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use | |
| IL280644A (en) | Magnesium serine compound and its use | |
| GB201820088D0 (en) | Opitical devices and methods | |
| GB201709840D0 (en) | Methods and medical uses | |
| IL267937A (en) | Amide compounds and their use | |
| ZA201901089B (en) | S1p1 agonist and application thereof | |
| EP3735277C0 (en) | MEDICAL MATERIALS AND DEVICES | |
| PL3768265T3 (pl) | Nowy, aktywny na poziomie ośrodkowego układu nerwowego agonista greliny i jego zastosowania w medycynie | |
| IL280369A (en) | Myokines and their uses | |
| EP3903741C0 (en) | BIOLOGICAL COATING AND IMPLANT | |
| IL269843B (en) | Converted N-arylethyl-2-arylquinoline-4-carboxamides and their use | |
| EP3815651C0 (en) | MEDICAL DEVICE AND PREPARATION METHOD THEREFOR | |
| EP3735141C0 (en) | CARTRIDGE AND ELECTRONIC VAPING DEVICE | |
| GB201806133D0 (en) | Methods and medical uses | |
| IL283540A (en) | Dock1 inhibitory compound and use thereof | |
| GB201802743D0 (en) | Medicament and use thereof | |
| IL278919A (en) | Combinations comprising tropifexor and cenicriviroc | |
| IL283315A (en) | Heterocyclic compounds and medical use thereof | |
| ZAF201801021S (en) | Amodular medical anchor | |
| GB201812776D0 (en) | New methods and uses | |
| GB201801180D0 (en) | Method and use |